German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a ...

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, and ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...

This Merck KGaA 2022 business report presents the course of business throughout the respective business year. The report complies with the disclosure requirement for corporate entities and ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

In a report released on October 4, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $140.00. The company’s shares closed ...

The Merck Index Online is an encyclopaedic database of chemical substances – an evolution of the printed reference work The Merck Index. While the content has a focus on chemicals and biologicals of ...

(RTTNews) - Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development collaboration to evaluate the combination of Exelixis ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...